论文部分内容阅读
目的探讨重组人干扰素α-1b雾化治疗小儿呼吸道病毒感染性疾病的临床疗效及安全性。方法在患儿家属知情同意下,采用随机、对照的临床试验设计,将375例小儿呼吸道病毒感染性疾病患儿分为250例治疗组和125例对照组,除常规治疗外,治疗组加用重组人干扰素α-1b雾化治疗,对照组加用利巴韦林雾化治疗;并且对治疗组中的240例患儿治疗前后红细胞、血小板、尿粪常规、肝肾功能、心肌酶的结果进行对比分析。结果共有357例纳入统计,其中治疗组240例,对照组117例,在发热、咽痛、咳嗽、喘憋、肺部啰音消失时间,住院日及治疗有效率等方面,治疗组与对照组比较差异均有统计学意义(P<0.01);且1个疗程后,治疗组除7例病毒性肺炎患儿心肌酶升高外,240例患儿其他各项指标均未发现异常,且用药过程中未见明显不良反应。结论重组人干扰素α-1b雾化治疗小儿呼吸道病毒感染性疾病安全有效,方法简单,值得临床推广。
Objective To investigate the clinical efficacy and safety of recombinant human interferon α-1b aerosol in the treatment of pediatric respiratory viral infectious diseases. Methods With the informed consent of children’s family members, 375 children with respiratory viral infectious diseases were divided into 250 treatment groups and 125 control groups using a randomized, controlled clinical trial design. In addition to the conventional treatment, the treatment group Recombinant human interferon α-1b atomization treatment, the control group plus ribavirin atomization treatment; and 240 cases of children in the treatment group before and after treatment of red blood cells, platelets, urine stool, liver and kidney function, myocardial enzymes The results of comparative analysis. Results A total of 357 cases were included in the statistics, including 240 cases in the treatment group and 117 cases in the control group. In the treatment group and the control group, the incidence of fever, sore throat, cough, wheezing, disappearance of pulmonary rales, hospitalization days, (P <0.01). After 1 course of treatment, except for 7 cases of viral pneumonia in the treatment group, the myocardial enzymes increased, the other 240 cases showed no abnormalities, and medication No obvious adverse reactions in the process. Conclusions Recombinant human interferon alfa-1b nebulization is safe and effective in the treatment of pediatric respiratory virus infectious diseases. The method is simple and worthy of clinical application.